Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients

Inclusion Criteria: * All patients was diagnosed within the past 12 months with type 2 diabetes patients (WHO, 1999 criteria ). * Not received oral anti-diabetic drugs or has been on short-term(1month) treatment that had been discontinued 3 months before enrollment. * 30 ≤ Age ≤ 70 years old, male or female. * HbA1c between 7% and 9% (7.0% ≤ HbA1c ≤9.0%). * 24 ≤ BMI ≤ 30 kg/m2. * Written Informed consent. Exclusion Criteria: * Subject with type 1 diabetes or gestational diabetes mellitus and other specific types DM. * Those who can not tolerate AGI or who is suffering GI disease. * Subject with repeated severe hypoglycemia and/or unawareness of hypoglycemia. * Known or suspected allergy to trial product(s) or related products. * Females of child bearing potential who are pregnant, breast-feeding or have the intention of becoming pregnant or not using adequate contraceptive methods throughout the trial * Impaired liver function, defined as ALT≥2 or AST≥ 2 times upper referenced limit times upper normal limit. * Any other clinically significant condition or major systemic diseases, including serious coronary heart disease, cardiovascular disease, cancer, TB, acute infection. * Endocrine diseases (hypo thyroidism, hyperthyroidism,Cushing's syndrome). * Uncontrolled hypertension(SBP≥180mmHg and/or DBP≥100mmHg). * Diabetic ketoacidosis; or hyperosmolar non-ketotic coma. * Concomitant treatment which influences blood glucose and bodyweight. * Impaired renal function(Cr≥ 1.5 mg/dl in male or Cr≥1.4 mg/dl in female). * Mental disorders; drug or other substance misuse. * Participation in any drug clinical trials during the past 3 months before enrolment.